GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cognition Therapeutics CGTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.60

+0.10%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Cognition Therapeutics — daily CGTX Delayed
Market value
$53.0m
Last close × shares
Volume
332.7k
Shares, 19 Nov 2026

About Cognition Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Cognition Therapeutics is based in Purchase, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CGTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $23.5m. At that date it held total assets of $48.4m and shareholders' equity of $34.3m.

In its own words

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.

Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer’s disease, or AD, and dementia with Lewy bodies, or DLB.

The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024.

The Company’s initial focus was on the development of zervimesine for the treatment of AD. We believe our evidence demonstrates that zervimesine displaces Aβ oligomers from their neuronal receptors. Based on this mechanism, we believe zervimesine has the potential to slow the loss of synapses and cognitive decline observed in AD. The direct healthcare costs to care for patients with AD and other dementias in the United States is estimated to exceed $350 billion.

Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗

More about Cognition Therapeutics →

Latest on Cognition Therapeutics

Our reporting

We have not reported on Cognition Therapeutics yet.

Next results

25 Mar 2027

Due on 25 Mar 2027. Analysts expect earnings of -0.07 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Cognition Therapeutics's ticker?

Cognition Therapeutics trades as CGTX on its US listing, under ISIN US19243B1026.

What was Cognition Therapeutics's last closing price?

0.60 on 19 Nov 2026. The figure is in USD and is never converted.

When does Cognition Therapeutics next report results?

Results are expected on 18 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.